Glucocorticoids and Cancer
Identifieur interne : 001D31 ( Main/Exploration ); précédent : 001D30; suivant : 001D32Glucocorticoids and Cancer
Auteurs : Miles A. PufallSource :
- Advances in experimental medicine and biology [ 0065-2598 ] ; 2015.
Abstract
Unlike other steroid hormone receptors, the glucocorticoid receptor (GR) is not considered an oncogene. In breast cancer, the estrogen receptor (ER) drives cell growth, proliferation, and metastasis, and the androgen receptor (AR) plays a similar role in prostate cancer. Accordingly, treatment of these diseases has focused on blocking steroid hormone receptor function. In contrast, glucocorticoids (GCs) work through GR to arrest growth and induce apoptosis in lymphoid tissue. Glucocorticoids are amazingly effective in this role, and have been deployed as the cornerstone of lymphoid cancer treatment for decades. Unfortunately, not all patients respond to GCs and dosage is restricted by immediate and long term side effects. In this chapter we review the treatment protocols that employ glucocorticoids as a curative agent, elaborate on what is known about their mechanism of action in these cancers, and also summarize the palliative uses of glucocorticoids for other cancers.
Url:
DOI: 10.1007/978-1-4939-2895-8_14
PubMed: 26216001
PubMed Central: 5546099
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 003252
- to stream Pmc, to step Curation: 003251
- to stream Pmc, to step Checkpoint: 001215
- to stream Ncbi, to step Merge: 007671
- to stream Ncbi, to step Curation: 007671
- to stream Ncbi, to step Checkpoint: 007671
- to stream Main, to step Merge: 001D34
- to stream Main, to step Curation: 001D31
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glucocorticoids and Cancer</title><author><name sortKey="Pufall, Miles A" sort="Pufall, Miles A" uniqKey="Pufall M" first="Miles A." last="Pufall">Miles A. Pufall</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26216001</idno><idno type="pmc">5546099</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546099</idno><idno type="RBID">PMC:5546099</idno><idno type="doi">10.1007/978-1-4939-2895-8_14</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">003252</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003252</idno><idno type="wicri:Area/Pmc/Curation">003251</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003251</idno><idno type="wicri:Area/Pmc/Checkpoint">001215</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001215</idno><idno type="wicri:Area/Ncbi/Merge">007671</idno><idno type="wicri:Area/Ncbi/Curation">007671</idno><idno type="wicri:Area/Ncbi/Checkpoint">007671</idno><idno type="wicri:doubleKey">0065-2598:2015:Pufall M:glucocorticoids:and:cancer</idno><idno type="wicri:Area/Main/Merge">001D34</idno><idno type="wicri:Area/Main/Curation">001D31</idno><idno type="wicri:Area/Main/Exploration">001D31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Glucocorticoids and Cancer</title><author><name sortKey="Pufall, Miles A" sort="Pufall, Miles A" uniqKey="Pufall M" first="Miles A." last="Pufall">Miles A. Pufall</name></author></analytic><series><title level="j">Advances in experimental medicine and biology</title><idno type="ISSN">0065-2598</idno><idno type="eISSN">2214-8019</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Unlike other steroid hormone receptors, the glucocorticoid receptor (GR) is not considered an oncogene. In breast cancer, the estrogen receptor (ER) drives cell growth, proliferation, and metastasis, and the androgen receptor (AR) plays a similar role in prostate cancer. Accordingly, treatment of these diseases has focused on blocking steroid hormone receptor function. In contrast, glucocorticoids (GCs) work through GR to arrest growth and induce apoptosis in lymphoid tissue. Glucocorticoids are amazingly effective in this role, and have been deployed as the cornerstone of lymphoid cancer treatment for decades. Unfortunately, not all patients respond to GCs and dosage is restricted by immediate and long term side effects. In this chapter we review the treatment protocols that employ glucocorticoids as a curative agent, elaborate on what is known about their mechanism of action in these cancers, and also summarize the palliative uses of glucocorticoids for other cancers.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Pufall, Miles A" sort="Pufall, Miles A" uniqKey="Pufall M" first="Miles A." last="Pufall">Miles A. Pufall</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5546099
|texte= Glucocorticoids and Cancer
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26216001" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |